CapsoVision reports 15% revenue growth in FY2025; completes $14M private placement

CapsoVision, Inc

Q4 2025 revenue $3.9M (+13% YoY); full year $13.6M (+15% YoY) driven by higher capsule sales.
Gross margin stable at 50% Q4 and 53% full year (vs 54% prior year).
Operating expenses $9.4M Q4 (+$3.0M YoY); full year $32.7M (+$6.4M) on CMOS sensor development and public company costs.
Cash $10.1M at Dec 31, 2025; completed $14M private placement in March 2026.
Submitted FDA 510(k) for AI-assisted module; 161,000+ patients used CapsoCam Plus as of Dec 31, 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CapsoVision, Inc reported the fourth quarter ended December 31, 2025 results: revenue $3.9 million.

Period: the fourth quarter ended December 31, 2025
Revenue: $3.9 million
Result: reported results

Exact text from the filing

Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CapsoVision, Inc reported the full year ended December 31, 2025 results: revenue $13.6 million.

Period: the full year ended December 31, 2025
Revenue: $13.6 million
Result: reported results

Exact text from the filing

Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.

View on SEC.gov

1435 earnings releases filed in the last 30 days. Browse all earnings releases →

CapsoVision, Inc filing history →

Source: SEC EDGAR

accession 0001378325-26-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.